All News

nerve.stim_.jpg

Vagal Nerve Stimulation in Rheumatoid Arthritis

d Jack Cush, MD

Lancet Rheumatology has reported the results of a proof of concept trial, wherein vagal nerve stimulation was shown to ameliorate RA disease activity. The intervention involved non-invasive stimulation of the auricular branch of the vagus nerve using a wearable vagus nerve stimulation device for up to 30 min per day, delivering pulses of 20 kHz.

Read Article
Lifestyle diet alcohol risk obesity

One-Third Rheumatoid Risk from Lifestyle

d Jack Cush, MD

Analysis of the NHANES (National Health and Nutrition Examination Survey) data suggests that one-third of the risk of developing rheumatoid arthritis (RA) in the USA is attributable smoking, obesity and alcohol intake.

Read Article
Low Persistence of Biologics in Psoriatic Arthritis A longitudinal observational cohort study of psoriatic arthritis (PsA) patients treated with biologic therapy finds relatively low persistence of selected biologic therapy in PsA patients. https://t.co/CzQnpAnttW https://t.co/uYU778rwod

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - "I Don't Know"--What to Say When you Don't Have a Diagnosis to Deliver https://t.co/HcJAXRYTyc

Links:

Dr. John Cush RheumNow ( View Tweet)

One-Third Rheumatoid Risk from Lifestyle Analysis of the NHANES data suggests that 1/3 of the risk of developing RA in the USA is attributable smoking, obesity and alcohol intake. https://t.co/jLLmEvXg2O https://t.co/ZG1hcJ7QVJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Download available--Maintaining a Healthy Immune System https://t.co/wiWzZldnik https://t.co/ZL3r3dHPC2

Links:

Dr. John Cush RheumNow ( View Tweet)
Abbvie has released data from KEEPsAKE-1 and KEEPsAKE-2 studies (1407 pts) showing Risankizumab (IL--23 inhibitor) is effective in Psoriatic arthritis; RIS Rx pts achieved ACR20 of 57% and 51% at week 24 (vs PBO 34% and 27%; p<0.001) https://t.co/wPQMqLnhOO

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of 24 studies finds pregnant women, w/ inflammatory disease, exposed to biologics had NO increased risk of congenital anomalies (adj OR 1.18; 0.88, 1.57), but had increased preterm births (OR 1.61; 1.37, 1.89) & low birth weight (OR 1.68) https://t.co/KqTDmfFf9H

Links:

Dr. John Cush RheumNow ( View Tweet)

French study of 782 men (50-85 years) with DISH found DISH was associated with increased vertebral fractures (OR 2.89; 95% CI, 1.15-7.28; P <.05), but Nonvertebral fractures were not associated with DISH (HR 0.72; 0.33-1.56). https://t.co/YoQ8r62pns

Links:

Dr. John Cush RheumNow ( View Tweet)

British registry 801 axial SpA pts; 646 did not hve fibromyalgia at baseline & 46 (7%) developed FM over time. Of 115 axSpa w/ baseline FM, 77 (2/3) recovered. FM more likely with high Dz activity ((OR 1.27) & widespread pain (OR 1.14) https://t.co/4jOdaXIJuB https://t.co/ruOYj5HmMX

Links:

Dr. John Cush RheumNow ( View Tweet)
Our Top January Tweet: Urate Lowering Therapy During Acute Gout Acute gout has its well-defined protocols, and most state that urate lowering therapy should be continued; but does ULT affect outcomes in an acute gout attack? https://t.co/aDHpU1qrlu https://t.co/6xDwyVjuyC

Links:

Dr. John Cush RheumNow ( View Tweet)
Multiple intraarticular steroid injxs NO better than placebo. Analysis of 6 RCTs show no diff in pain than PBO (−0.47, 95% CI −0.62, 0.31). 14 RCTs + 2 Observ. studies show IA steroids may cause mor cartilage loss or risk of joint replacement (HR 2.54) https://t.co/jCLq4jWn4Y

Links:

Dr. John Cush RheumNow ( View Tweet)

Everyone longs for normal. Normal may have changed, died, or been put off. But tomorrow morning, normal is waking up and looking to you for guidance

Dr. John Cush RheumNow ( View Tweet)

Sign up for RheumNow Live, March 20 and 21st. CME credits available. https://t.co/uwxOVh142F https://t.co/GqkCLBGl62

Links:

Dr. John Cush RheumNow ( View Tweet)
Download our latest resource--Televideo Joint Exam Checklist. https://t.co/XnyCW2eak8

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow podcast is now up--listen in on SoundCloud, RheumNow or Apple/Android car play. Rheumatology Burnout?--Dr. Cush reviews the top articles from the week of 1/29/21. https://t.co/HiX7qMFU6b https://t.co/KbaZ6XjHG6

Links:

Dr. John Cush RheumNow ( View Tweet)
Calculating Serious Infection Risk in IMID Patients Predictive modeling of data derived from the DANBIO registry (of treated IMID patients) revealed a 4 fold increased risk of serious infection in those starting biologic DMARD treatment. Read more: https://t.co/i2GwiCvCx6 https://t.co/9sZ79LyZ7u

Links:

Dr. John Cush RheumNow ( View Tweet)
High Placebo Responses in SLE Trials A systematic review in randomized controlled trials (RCTs) of non-renal, non-neuropsychiatric systemic lupus erythematosus (SLE) patients showing unexpectedly high placebo responses. Read more: https://t.co/zUPsVFEz4n https://t.co/Gk7ke4hBwY

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic Podcast for the week of Jan 29 - Pearls from Practice This wk: Arthritis &Crohn's Rhabdo or Not Dadgummit, Where's Waldos COVID Vaccine? "I Don't Know" A Tale of Two Gouts https://t.co/7ndYSOgh5R or listen on iTunes https://t.co/FHJv01AAbC https://t.co/780P7Bdw8F

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is up - Rheumatology Burnout (1.29.2021) - Vaccine #s, Colchicine in COVID, Rheums #2 in Burnout? Endometriosis & RA risk, Comorbidity as predictors. https://t.co/HiX7qMFU6b or listen on iTunes>>https://t.co/FHJv01AAbC or on SoundCloud>> https://t.co/0BfqGhxgQj https://t.co/j9nHMs4C6d

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×